Teva commences commercial launch of Escitalopram Oxalate Tablets

NewsGuard 100/100 Score
Editorial Checklist Reviewed
Mar 15 2012Teva

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that it has commenced commercial launch of Escitalopram Oxalate Tablets, the Company's generic version of Forest Laboratories' depression and generalized anxiety disorder treatment, Lexapro® Tablets. The brand product had annual sales of approximately $2.9 billion in the United States, based on IMS sales data.

As the first company to file an Abbreviated New Drug Application (ANDA) containing a paragraph IV certification for this product, Teva has been awarded a 180-day period of marketing exclusivity.

Source:

Teva

Posted in: Medical Condition News | Pharmaceutical News

Tags: , , , , , , , , , , , , ,

Comments (0)

Suggested Reading

Pembrolizumab enhances breast cancer treatment regardless of age or menopausal status
Study highlights global fertility decline and its implications for the future
SCIEX’s Jose Castro-Perez Reveals How They're Setting New Standards in Mass Spectrometry
Innovative levodopa infusion pump trial shows promise for reducing Parkinson's symptoms
Supply chain assessment and management, optimizing pharmaceutical supply chains
Common HIV drugs linked to reduced Alzheimer's disease risk
The Lancet Breast Cancer Commission: Tackling inequalities, hidden costs, and empowering patients
Recycled food waste may be contaminated with pharmaceutical residues, research reveals

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
LabVantage celebrates customer success with record number of software deployments in FY 2024